Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Residual Anti-Xa Activity of Enoxaparin Before Elective Surgery
NCT03296033Phase 4Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2017
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of enoxaparin in thromboembolism, sponsored by Wake Forest University Health Sciences. Started Oct 2017; status: terminated.
02
Drugs
enoxaparin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT03296033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296033.